-
1.发明申请CRYSTALLINE LESTAURTINIB HYDRATES AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMIACETONITRILEATE AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMITETRAHYDROFURANATE 审中-公开晶体蛋白酶水解物和晶体蛋白乙酰胆碱乙酰胆碱酯酶和晶体蛋白酶抑制剂乙酸海藻酸
公开(公告)号：WO2007075307A2
公开(公告)日：2007-07-05
申请号：PCT/US2006047086
申请日：2006-12-08
Applicant: ABBOTT LAB , DZIKI WALTER , SUBBARAO GOWDAHALLI N , HENRY RODGER F
Inventor： DZIKI WALTER , SUBBARAO GOWDAHALLI N , HENRY RODGER F
CPC classification number: C07D498/22
Abstract: Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemicetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate, processes to reproducibly make them and methods of treating patients using them are disclosed.
Abstract translation: 公布了结晶的赖蕊啶水合物和结晶的赖tin啶半水合物硫代乙酸酯和结晶赖tin啶半水合物半脱氢四氢呋喃酸盐，可重复制备它们的方法和使用它们治疗患者的方法。
-
公开(公告)号：WO9943299A2
公开(公告)日：1999-09-02
申请号：PCT/US9903675
申请日：1999-02-19
Applicant: ABBOTT LAB
Inventor： FU LU MOU YING , BAUER JOHN F , DZIKI WALTER , TAYLOR VICTOR E , WANG ZHENG
CPC classification number: A61K9/0095
Abstract: The present invention relates to a pharmaceutical composition and concentrate suitable for oral administration comprising a hydrophilic drug solubilized in a lipophilic phase comprising a fatty acid, and water; an oral formulation comprising uniform dispersion of the pharmaceutical concentrate in an aqueous phase optionally comprising a self-emulsifying material; and to a process of making the same.
Abstract translation: 本发明涉及适于口服给药的药物组合物和浓缩物，其包含溶解在包含脂肪酸的亲脂相中的亲水性药物和水; 包含药物浓缩物均匀分散在任选包含自乳化材料的水相中的口服制剂; 并涉及制造它的过程。
-
公开(公告)号：CA2578824A1
公开(公告)日：2006-03-30
申请号：CA2578824
申请日：2005-09-19
Applicant: ABBOTT LAB
Inventor： WARDROP JAQUELINE , ZHANG GEOFF G , RASMUSSEN MICHAEL W , GOLDSTEIN MARK , LU ZIQI , LINTON CATHIE L , DZIKI WALTER
IPC: C07D405/10 , A61K31/4025 , A61P35/00
-
4.发明专利
公开(公告)号：CA2631641A1
公开(公告)日：2007-06-21
申请号：CA2631641
申请日：2006-12-08
Applicant: ABBOTT LAB
Inventor： DZIKI WALTER , HENRY RODGER F , SUBBARAO GOWDAHALLI N
IPC: C07D498/22 , A61K31/55 , A61P35/02
Abstract: Lestaurtinib Crystalline Form 1, isolated crystalline lestaurtinib anhydrate and amorphous lestaurtinib, processes to reproducibly make them and methods of treating patients using them.
-
Patent Agency Ranking
公开(公告)号：ZA9901539B
公开(公告)日：1999-08-25
申请号：ZA9901539
申请日：1999-02-25
Applicant: ABBOTT LAB
Inventor： LU MOU YING FU , DZIKI WALTER , WANG ZHENG , BAUER JOHN F , TAYLOR VICTOR E
CPC classification number: A61K9/0095
-
公开(公告)号：ZA991539B
公开(公告)日：1999-08-25
申请号：ZA991539
申请日：1999-02-25
Applicant: ABBOTT LAB
Inventor： LU MOU YING FU , DZIKI WALTER , WANG ZHENG , BAUER JOHN F , TAYLOR VICTOR E
-
公开(公告)号：CA2631686A1
公开(公告)日：2007-07-05
申请号：CA2631686
申请日：2006-12-08
Applicant: ABBOTT LAB
Inventor： SUBBARAO GOWDAHALLI N , DZIKI WALTER , HENRY RODGER F
IPC: A61K31/553 , A61P35/00 , C07D498/22
Abstract: Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemicetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate, processes to reproducibly make them and methods of treating patients using them are disclosed.
-
公开(公告)号：MX2007003158A
公开(公告)日：2007-05-15
申请号：MX2007003158
申请日：2005-09-19
Applicant: ABBOTT LAB
Inventor： ZHANG GEOFF G , DZIKI WALTER , LU ZIQI , RASMUSSEN MICHAEL W , WARDROP JAQUELINE , GOLDSTEIN MARK , LINTON CATHIE L
IPC: A61K31/00 , C07D405/10 , A61P35/00
Abstract: La presente invencion se refiere a la forma cristalina 2 del clorhidrato de atrasentan, a composiciones que la contienen, y a metodos de tratamiento de enfermedades e inhibicion de reacciones fisiologicas adversas, utilizandola.
-
公开(公告)号：AU2870899A
公开(公告)日：1999-09-15
申请号：AU2870899
申请日：1999-02-19
Applicant: ABBOTT LAB
Inventor： LU MOU YING FU , BAUER JOHN F , DZIKI WALTER , TAYLOR VICTOR E , WANG ZHENG
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.037 seconds)
